Prologis Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Prologis Inc trades at $129.52 (market cap $120.98B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Prologis Inc is far larger — about 4.8× Royalty Pharma plc Class A Ordinary Shares's market cap, and Prologis Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| PLD | RPRX | |
|---|---|---|
Market Cap | $120.98B | $25.27B |
Volume | 3,604,776 | 3,671,183 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $63.96 |
52-Week Low | $111.23 | $35.44 |
Typical Hold Time | 102 Days | 0 Days |
Enterprise Value | $155.72B | $32.50B |
Dividend Yield | 3.36% | 1.66% |
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $129.29, up 0.47% today, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results pending. Revenue grew to $8.79B in 2025, and net income margin stands strong at 45.79%. Recent news highlights strong leasing activity and data center growth potential, though the stock faces near-term resistance near $129.
The outlook for PLD is positive, supported by robust fundamentals and analyst consensus favoring a buy rating with a $155.15 price target. Key opportunities include e-commerce and data center demand driving rent growth. Risks involve rising debt levels, with debt-to-asset ratio increasing to 37.2% in 2025, and broader REIT sector volatility amid interest rate concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →